Protection of Mice Orally Infected With Shiga Toxin–Producing Citrobacter rodentium Treated With Nanobody Multimer
Authors:
- Abhineet SheoranASAbhineet Sheoran
- Amanda J MartinotAMAmanda J Martinot
- Sally R RobinsonSRSally R Robinson
- Anne FuAFAnne Fu
- Cara MartoneCMCara Martone
- Denise DayaoDDDenise Dayao
- Charles B ShoemakerCSCharles B Shoemaker
- Saul TziporiSTSaul Tzipori
Open Access
- 6 June 2026
- Vol. 13 (6)
Abstract
Shiga toxin (Stx)–producing Escherichia coli (STEC) colonizes the gut and causes enteritis through bacterial attachment-effacement (A/E), leading to mucosal damage. This facilitates systemic uptake of Stx, which can often lead to hemolytic-uremic syndrome (HUS) and acute renal failure, particularly in children <5 years of age. STEC infections expressing Stx2 variants are a major risk factor for HUS. Beyond patients receiving supportive care, there is no treatment for STEC-mediated HUS, and antibiotics are contraindicated. The 3- to 7-day prodromal interval between onset of STEC diarrhea and HUS offers a window for intervention for diarrheic patients, contacts thereof, or individuals exposed to the source of infection. Citrobacter rodentium (Cr), a mouse pathogen that exhibits mucosal bacterial A/E, was genetically constructed to express Stx2d (Cr-Stx2d). This, along with a Cr parent strain carrying the kanamycin gene, were used to model STEC in mice. Mice were treated intraperitoneally with a broad subtype-specific, Stx-neutralizing nanobody multimer fused to the human IgG1 Fc domain (VNA2-Stx/hFc). When a single treatment was administered as late as 4 days after Cr-Stx2d challenge, likely within the human STEC-HUS window of intervention, complete protection of mice was achieved. This Cr-Stx2d model, which mimics elements of human STEC infections by causing mucosal gut lesions and systemic Stx2d-mediated kidney damage, will help evaluate specific treatments against STEC-HUS, as demonstrated here with VNA2-Stx/hFc-treated mice given a single injection well after bacterial challenge. This product should be safe, simple, and economical to manufacture.Keywords
This publication has 23 references indexed in Scilit:
- Stx2-Specific Human Monoclonal Antibodies Protect Mice against Lethal Infection with Escherichia coli Expressing Stx2 VariantsInfection and Immunity, 2003
- Production and Characterization of Protective Human Antibodies against Shiga Toxin 1Infection and Immunity, 2002
- Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 InfectionInfection and Immunity, 2002
- A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humansNature Medicine, 2000
- Associations between Virulence Factors of Shiga Toxin-ProducingEscherichia coliand Disease in HumansJournal of Clinical Microbiology, 1999
- The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses1996
- The Epidemiology of Infections Caused by Escherichia coli O157: H7, Other Enterohemorrhagic E. coli, and the Associated Hemolytic Uremic SyndromeEpidemiologic Reviews, 1991
- Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type IIInfection and Immunity, 1990
- Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects.Archives of Disease in Childhood, 1990
- Toxin Genotypes and Plasmid Profiles as Determinants of Systemic Sequelae in Escherichia coli O157:H7 InfectionsThe Journal of Infectious Diseases, 1989